Advertise on podcast: TD Cowen Insights

Recorded on 09/30/2026 TD Cowen financial policy analyst Jaret Seiberg hosts TD Cowen's Two Cents Podcast, which this month focuses on the upcoming midterm election and what it could mean for financial, crypto, and housing policy. And we have TD Cowen's Scott Smith for an update on the market in advance of the start of Q3 earnings season. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 09/24/26 TD Cowen Analyst Jason Gabelman speaks with Kevin Mitchell, CFO of Phillips 66, a downstream energy company. They discuss recent market volatility driven by geopolitical events, investing in growth to meet the world's needs for energy, and balancing growth against shareholder returns. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 09/18/26  Oxbow Partners’ Manmeet Singh Bawa expects AI to automate brokers’ information processing and administration, shifting value to judgment, advocacy, negotiation, and strategic risk advice. Data-rich brokers and focused specialists should gain; undifferentiated mid-tier firms face pressure. The winning model: AI advises; humans decide—and remain accountable. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 09/03/26 AI is generating potential new drug candidates faster than ever, but clinical trials can take years to complete. So what happens when innovation outruns the system designed to test it? In this episode, we speak with Paradigm Health's Chief Strategy and Growth Officer, Jonathan Hirsch, who shares how AI is helping sponsors recruit patients faster, reduce administrative burden, and potentially shave years off the clinical development process. Paradigm Health is a clinical research company that aims to make clinical trials more accessible for patients, researchers, and study sponsors through a seamless, AI-powered platform. Providing solutions for both trial sponsors and research sites, Paradigm Health aims to break down barriers across the clinical trial ecosystem through its Real-Time Clinical Trial infrastructure, which is being implemented at health care provider organizations. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 09/18/26 In this episode, Roman Schweizer, TD Cowen’s WRG geopolitics & defense analyst, is joined an All-Star reporter roundtable to discuss the ongoing war between the USA and IRI, including the latest flareup between KSA & Houthis and the Trump Administration's OK to sell KSA the long-coveted F-35. We also discuss the congressional outlook, the Air Force Association's annual conference in DC, and other issues like the surprise revelation about USA space weapons, a growing political debate about AI, and DoW's latest memo on pricing and cost transparency from DepSecWar Feinberg. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 09/10/26 Senior biotech analyst Ritu Baral hosts Linnea Cipriano, partner in Goodwin's IP litigation practice. Cipriano explains why psychedelic therapies often require a different IP playbook than standard pharmaceuticals. Unlike newly synthesized compounds with limited prior art and composition-of-matter protection, first-generation psychedelics are long-studied molecules where prior art presents a significant patent challenge, often more so than many compounds' natural origin. We also discuss how sponsors can build layered protection through formulations, polymorph/crystalline forms, delivery devices, manufacturing processes, and method-of-use claims. Cipriano emphasizes the balance between patentability and enforceability: narrow claims may overcome prior art but are harder to prove infringed; polymorph and crystalline form patents may be obtainable yet easier for competitors to design around. Cipriano also explains why formulation patents may offer a better balance of obtainability and enforceability, why device and manufacturing patents can remain valuable even when they are not Orange Book-listable, and how treatment-model claims become more defensible when patient selection, dosing, monitoring, and follow-up are mandatory rather than optional. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 08/25/26 In this episode, we sat down with Omead Ostadan, CEO of Cellanome, and one of the key leaders behind the genomics revolution. Drawing on nearly three decades spanning Solexa, Illumina, and now Cellanome, Omead shares his perspective on the future of biological innovation, the intersection of AI and biology, and why larger, richer biological datasets are key to unlocking the next wave of discovery. We also explore Cellanome's pioneering approach to studying living cells, lessons from building category-defining companies, and where the next major breakthroughs in life sciences may emerge.   https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 09/03/26 TD Cowen financial policy analyst Jaret Seiberg hosts TD Cowen's Two Cents Podcast, which this month features a conversation on housing with TD Securities equity analyst Max Rakhlenko and TD Securities macro analyst Eli Nir. We discuss the impact of rates and inflation on housing and look at what to expect in the coming year. And as always, we have TD Cowen's Scott Smith for an update on the market. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 07/10/26 TD Cowen's Machine Medicine: AI & Health Care podcast series takes on the cross-sector revolution in artificial intelligence and breaks it down one piece at a time. We highlight some of the biggest misconceptions about how AI is and can be used in different health care settings and aim to contextualize the latest and most impactful developments in a field defined by rapid innovation. In this episode, TD Cowen health care analyst Brendan Smith hosts Sid Jain, SVP of Clinical Development & Data Science at Recursion, to dive into what it means to build out a truly proprietary ClinTech platform and how Recursion is "future proofing" its clinical development portfolio with AI. We explore the greatest challenges drug developers face within clinical development and how novel clinical technology platforms tackle these bottlenecks to break down barriers with the use of next-gen AI/ML tools. We also discuss how unlocking efficiencies within the clinical space can read through to R&D decision-making strategies and what investors are missing about AI within this ecosystem today. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 07/15/26 Authentic Canadian Craftsmanship & Rebellious Relevance. We hosted CEO Ellen Kinney to discuss the brand's global growth opportunity as it balances outerwear leadership and luxury craftsmanship with broader lifestyle ambitions. Key themes included selective distribution, co-creation over celebrity, disciplined inventory management, and maintaining brand authenticity while scaling internationally. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 08/04/26 David Beckham's Clinically Validated, NSF-Certified Wellness: Prenetics. We host Danny Yeung, Co-Founder & CEO of IM8 & Prenetics, to discuss building one of consumer health's fastest-growing wellness brands with Co-Founder David Beckham. We explore longevity innovation, clinical validation, DTC scaling, subscription economics, global expansion, & the future of science-backed preventive health.   https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 07/17/26 TD Cowen senior analyst Ritu Baral hosts Michael McCaughan, founder of Prevision Policy, a leading provider of regulatory and reimbursement policy analysis for the biopharma industry. Discussion focused on the evolving regulatory landscape for psychedelic treatments. McCaughan views FDA as already receptive to psychedelics from the bottom up, with the recent executive order on accelerating psychedelic development and approval adding clear new top-down support. He does not believe the updated 2026 FDA industry guidance meaningfully changes the approvability bar for psychedelic sponsors, especially those with NDAs in progress. He views the recommendation for 12-month blinded follow-up as unlikely to be an approvability issue for these near term, and even Ph3 programs, although it could influence label language, durability claims, and claims on repeat dosing. On safety, he expects FDA to focus on if benefit outweighs key risks, including suicidality, abuse potential, and class-specific concerns such as cardiovascular or valvulopathy signals. He also expects a REMS framework anchored by in-office administration and misuse prevention, likely informed by Spravato but tailored to the psychedelic treatment model. Importantly, he believes FDA and DEA are likely to work together to minimize the gap between approval and rescheduling, though process and bureaucracy remain key timing variables. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 08/06/26 TD Cowen financial policy analyst Jaret Seiberg hosts TD Cowen's Two Cents Podcast, which this month features a conversation with Moshe Orenbuch, an equity analyst at TD Cowen who focuses on the consumer finance sector. We talk about credit growth, credit quality, and policy challenges. Also, TD Cowen's Scott Smith gives an assessment of bank earnings season. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 07/15/26 Learn About Global Wholesale Platform Powering Independent Retail. We host Jeff Kolovson, co-founder & COO of Faire, a wholesale technology platform that helps retailers discover brands and products to stock. We discuss how the company is transforming wholesale for independent retailers and brands, and cover topics including AI-powered discovery, network effects, and the future of trade shows. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recorded on 07/15/26 In this episode, TD Cowen's health care analyst Brendan Smith hosts Patrick Finn, President and COO of Twist Bioscience, to explore how companies like Twist are capitalizing on the evolving drug development landscape and what impact biopharma's ramping use of AI is having on life science tools providers across the industry. We discuss how big tech companies are expanding into the life sciences, whether dry-lab-first innovators could be the drug developers of the future, and how we should think about what it takes to "win" in the space moving forward. We also aim to unpack whether wet lab validation will remain an essential part of drug development for the foreseeable future and how durable this wave of data demand could be over the coming years. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.